Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 18/20 | 0.64 |
| ▸ | MMP3 | P08254 | 11/20 | 0.64 |
| ▸ | MMP1 | P03956 | 3/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.64 |
| ▸ | MMP14 | P50281 | 1/20 | 0.64 |
| ▸ | BMP1 | P13497 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6412003 | 0.91 | MMP2 (0.64) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6413235 | 0.90 | MMP2 (0.65) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL8665571 | 0.89 | MMP2 (0.80) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL8667839 | 0.89 | MMP2 (0.64) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL8652786 | 0.89 | MMP2 (0.64) | MMP2MMP3 | |
| SCHEMBL8664107 | 0.89 | MMP2 (0.80) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL8663579 | 0.88 | MMP2 (0.62) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6417777 | 0.87 | MMP3 (0.63) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6418850 | 0.87 | MMP2 (0.64) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL7784697 | 0.82 | MMP2 (0.52) | MMP2MMP3MMP1MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0712390-B1 | SUCCINAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS GELATINASE AND COLLAGENASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 1998-12-09 | — | — | EP | claimed |
| EP-0712390-A1 | SUCCINAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS GELATINASE AND COLLAGENASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1996-05-22 | — | — | EP | claimed |
| WO-1995004033-A1 | SUCCINAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS GELATINASE AND COLLAGENASE INHIBITORS | CELLTECH LIMITED (GB) | 1995-02-09 | — | — | WO | claimed |
| US-20250090586-A1 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2025-03-20 | — | — | US | disclosed |
| US-12076347-B2 | Methods for production of platelets from pluripotent stem cells and compositions thereof | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2024-09-03 | — | — | US | disclosed |
| US-20230028239-A1 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2023-01-26 | — | — | US | disclosed |
| US-11400118-B2 | Methods for production of platelets from pluripotent stem cells and compositions thereof | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2022-08-02 | — | — | US | disclosed |
| CN-114558032-A | Method for preparing platelets from pluripotent stem cells and composition thereof | 安斯泰来再生医药协会 | 2022-05-31 | — | — | CN | disclosed |
| EP-3973967-A1 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | Astellas Institute for Regenerative Medicine (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2012-05-31 | — | — | US | disclosed |
| EP-2295088-A1 | Improved bone graft | Osteotech, Inc., (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-0712390-B1 | SUCCINAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS GELATINASE AND COLLAGENASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | MMP8, MMP1, TIMP3 | MMP2 5/4885MMP3 11/4885MMP1 2/4885 |
| US-20230028239-A1 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | THPO, PDGFRA, PDGFRB | MMP2 3559/4885MMP3 2499/4885MMP1 3520/4885 |
| US-11400118-B2 | Methods for production of platelets from pluripotent stem cells and compositions thereof | THPO, PDGFRA, PDGFRB | MMP2 3559/4885MMP3 2499/4885MMP1 3520/4885 |
| US-20250090586-A1 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | THPO, PDGFRA, PDGFRB | MMP2 3559/4885MMP3 2499/4885MMP1 3520/4885 |
| US-12076347-B2 | Methods for production of platelets from pluripotent stem cells and compositions thereof | THPO, PDGFRA, PDGFRB | MMP2 3559/4885MMP3 2499/4885MMP1 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.